Gly-Pro-pNA (hydrochloride) (Synonyms: Gly-Pro pnitroanilide, GP-pNA) |
| カタログ番号GC18201 |
Gly-Pro-pNA (hydrochloride)は、循環酵素であるジペプチダーゼIV（DPP IV）によって切断される発色基質である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 103213-34-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Gly-Pro-pNA (hydrochloride) is a chromogenic substrate that can be cleaved by the circulating enzyme, dipeptidyl peptidase IV (DPP IV). Enzyme activity can be quantified by colorimetric detection of free p-nitroanilide at 405 nm. This substrate can be used to screen for DPP IV inhibitors.[5].
Mare whey proteins show good DPP-IV inhibitory activity in vitro，have the able to inhibit DPP-IV from degrading Gly-Pro-pNA (hydrochloride) Gly-Pro-pNA (hydrochloride) [1]. The in vitro DPP-IV inhibitory activities of quinoa protein hydrolysates can determined using Gly-Pro-pNA (hydrochloride) as a substrate[2]. Gly-Pro-pNA (hydrochloride) can also be used to evaluate the activity of DPP-IV in human serum[3]. Demonstrating that DPP IV in diabetic patients is not very different from that in normal conditions[4]. Gly-pro p-nitroanilide hydrochloride was used as a substrate to detect DPPIV level in patients with Polycystic syndrome (PCOS) ，a deregulation of DPP4 serum levels could be an additional characteristic of the metabolic imbalances associated with PCOS[5]
Using Gly-Pro-pNA (hydrochloride) as substrate can assess the enzymatic activity and biochemical status of dipeptidyl peptidase IV (DPP IV)in patients with rheumatoid arthritis[6]
References:
[1]. Song JJ, Wang Q, et,al. Identification of dipeptidyl peptidase-IV inhibitory peptides from mare whey protein hydrolysates. J Dairy Sci. 2017 Sep;100(9):6885-6894. doi: 10.3168/jds.2016-11828. Epub 2017 Jul 12. PMID: 28711271.
[2]. You H, Wu T, et,al. Preparation and identification of dipeptidyl peptidase IV inhibitory peptides from quinoa protein. Food Res Int. 2022 Jun;156:111176. doi: 10.1016/j.foodres.2022.111176. Epub 2022 Mar 19. PMID: 35651037.
[3]. Yeganeh F, Mousavi SMJ, et,al. Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis. Clin Rheumatol. 2018 Dec;37(12):3183-3190. doi: 10.1007/s10067-018-4268-y. Epub 2018 Aug 22. PMID: 30136129.
[4]. Sun AL, Deng JT, et,al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res. 2012 Oct;9(4):301-8. doi: 10.1177/1479164111434318. Epub 2012 Mar 2. PMID: 22388283.
[5]. Blauschmidt S, Greither T, et,al. Dipeptidyl peptidase 4 serum activity and concentration are increased in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017 Dec;87(6):741-747. doi: 10.1111/cen.13444. Epub 2017 Sep 13. PMID: 28799235.
[6]. Mavropoulos JC, Cuchacovich M, et,al. Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. J Rheumatol. 2005 Nov;32(11):2116-24. PMID: 16265688.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *